Medical Therapy for Calcific Aortic Stenosis

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 17, Issue 2, 2012, Pages 133-138

  Salas, Maria J ^a   Santana, Orlando ^a   Escolar, Esteban ^a   Lamas, Gervasio A ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

angiotensin; cardiovascular disease; heart disease; statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL; AORTA VALVE STENOSIS; CALCINOSIS; DISEASE COURSE; HEART VALVE REPLACEMENT; HOSPITALIZATION; HUMAN; METHODOLOGY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ANIMALS; AORTIC VALVE STENOSIS; CALCINOSIS; DISEASE PROGRESSION; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84867189029     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248411416504     Document Type: Review

References (40)

1. Stewart BF Siscovick D Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular health study. J Am Coll Cardiol. 1997; 29(3):630-634.
2. Carabello BA Paulus WJ. Aortic stenosis. Lancet. 2009; 373(9667):956-966.
3. Rosenhek R Binder T Porenta G, et al. Predictors of outcome in severe asymptomatic aortic stenosis. N Engl J Med. 2000; 343(9):611-617.
4. Rajamannan NM. Calcific aortic stenosis: lessons learned from experimental and clinical studies. Arterioscler Thromb Vasc Biol. 2009; 29(2):162-168.
5. Novaro GM Tiong IY Pearce GL Lauer MS Sprecher DL Griffin BP. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001; 104(18):2205-2209.
6. Parolari A Loardi C Mussoni L, et al. Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention. Eur J Cardiothorac Surg. 2009; 35(3):493-504.
7. Rajamannan NM Bonow RO Rahimtoola SH. Calcific aortic stenosis: an update. Nat Clin Pract Cardiovasc Med. 2007; 4(5):254-262.
8. Cawley PJ Otto CM. Prevention of calcific aortic valve stenosis-fact or fiction? Ann Med. 2009; 41(2):100-108.
9. Chua D Kalb K. Statins and progression of calcified aortic stenosis. Ann Pharmacother. 2006; 40(12):2195-2199.
10. Otto C Kuusisto J Reichenbach D Gown AM O'Brien KD, Characterization of the early lesion of “degenerative” valvular aortic stenosis. Circulation. 1994; 90(2):844-853.
11. Pedersen TR. Overview of clinical trials on calcific aortic stenosis. Eur Heart J. 2008; 10 (S): E31-E40.
12. Aronow WS Ahn C Kronzon I Glodman ME. Association of coronary risk factors and use of statins with progression of mild valvular stenosis in older persons. Am J Cardiol. 2001; 88(6):693-695.
13. Bellamy MF Pellikka PA Klarich KW Tajik AJ Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol. 2002; 40(10):1723-1730.
14. Moura LM Ramos SF Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007; 49(5):554-561.
15. Cowell SJ Newby DE Prescott RJ, et al. Scottish aortic stenosis and lipid lowering trial, impact on regression (SALTIRE) investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005; 352(23):2389-2397.
16. Rossebø AB Pedersen TR Boman K, for the SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008; 359(13):1343-1356.
17. Chan KL Teo K Dumesnil JG Ni A Tam J. ASTRONOMER Investigators. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010; 121(2):306-314.
18. Principal investigator: Griffin, B. The Cleveland Clinic. The effect of statin therapy (Atorvastatin) on the progression of calcific valvular aortic stenosis. Clinicaltrial gov NCT00590135.
19. Principal investigator: Sanchez, P. Hospital Universitario Gregorio Marañón de Madrid. Double blind randomized phase IV clinical trial to evaluate the efficacy of gluvastatin on inflammatory markers in the haemodynamic progression of degenerative aortic stenosis. The AORTICA 1 Study. Clinicaltrial gov NCT00404287.
20. Walther C. University of Leipzig. Statin therapy in asymptomatic aortic stenosis. Clinicaltrial gov NCT00176410.
21. Routledge HC Townend JN. ACE inhibition in aortic stenosis: dangerous medicine or golden opportunity? J Hum Hypertens. 2001; 15(10):659-667.
22. Rosenhek R Rader F Loho N, et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation. 2004; 110(10):1291-1295.
23. Freeman RV Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation. 2005; 111: 3316-3326.
24. Newby DE Cowell SJ Boon NA. Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both? Heart. 2006; 92(6):729-734.
25. O'Brien KD Probstfield JL Caulfield MT, et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med. 2005; 165(8):858-862.
26. O'Brien K Zhao X Shavelle D. Hemodynamic effects of the angiotensin converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J Investig Med. 2004; 52(3):185-191.
27. Jimenez-Candil J Bermejo J Yotti R, et al. Effects of angiotensin converting enzyme inhibitors in hypertensive patients with aortic valve stenosis: a drug withdrawal study. Heart. 2005; 91(10):1311-1318.
28. Rigshospitalet, Denmark. Acute haemodynamic effects of treatment with Ace-inhibitors in patients with symptomatic aortic stenosis (ACCESS). Clinicaltrial gov NCT00252317.
29. Kupari M. Helsinki University Central Hospital. The Potential of Candesartan to Retard the Progression of Aortic Stenosis Influences of Medical Therapy to the Atheroinflammatory Process in Stenotic Aortic Valves. Clinicaltrial gov NCT00699452.
30. Rajamannan NM Subramaniam M Rickard D, et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 2003; 107(17):2181-2184.
31. Vattikuti R Towler DA. Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab. 2004; 286(5):E686-E696.
32. Rubin MR Silverberg SJ. Vascular calcification and osteoporosis-the nature of the nexus. J Clin Endocrinol Metab. 2004; 89(9):4243-4245.
33. Ortlepp JR Hoffmann R Ohme F Lauscher J Bleckmann F Hanrath P. The vitamin D receptor genotype predisposes to the development of calcific aortic stenosis. Heart. 2001; 85(6):635-638.
34. Green JR. Bisphosphonates: preclinical review. Oncologist. 2004; 9(suppl 4):3-13.
35. Reszka AA Rodan GA. Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem. 2004; 4(7):711-719.
36. Rapoport HS Connolly JM Fulmer J, et al. Mechanisms of the in vivo inhibition of calcification of bioprosthetic porcine aortic valve cusps and aortic wall with triglycidylamine/mercaptobisphosphonate. Biomaterials. 2007; 28(4):690-699.
37. Idris AI Rojas J Greig IR Van't Hof RJ Ralston SH. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int. 2008; 82(3):191-201.
38. Skolnick AH Osranek M Formica P Kronzon I. Osteoporosis treatment and progression of aortic stenosis. Am J Cardiol. 2009; 104(1):122-124.
39. Frontera G. Hospital Universitario Son Duret. Value of oral phytate (InsP6) in the prevention of progression of the cardiovascular calcifications (CALCIFICA). Clinicaltrial.gov NCT01000233.
40. Koos R. RWTH Aachen University. Vitamin K Supplement for Inhibition of the Progress in Aortic Valve Calcification. Clinicaltrial gov NCT00785109.